Minal Dakhave

About

Dr. Minal Dakhave is a healthcare and diagnostics leader with over 15 years of experience in molecular diagnostics, translational research, and product innovation. She has led the development and commercialization of 75+ diagnostic products spanning infectious diseases, oncology, and genetics. Known for pioneering India’s first COVID-19 RT-PCR test and the world’s first point-of-care molecular COVID test (CoviSwift™), she combines deep scientific expertise with regulatory strategy and market impact.

Dr. Dakhave currently leads Medical Affairs at Dognosis, where she is spearheading multi-site clinical studies in India for breath-based early cancer detection. She has also held key leadership roles at Mylab Discovery Solutions, where she directed the launch of high-impact molecular diagnostics including NAT kits, TB drug resistance and HPV screening solutions at national level.

Her research contributions include 10+ peer-reviewed publications, 5 granted patents, and multiple international conference presentations (ASCO, IACR, Virocon). She serves as an academic editor (PLOS ONE) and reviewer for prominent journals and has received recognitions such as the Padma Award nomination (2020), Best Researcher Award (2023), and Rising Star Award (2021).

Her areas of interest include molecular innovation, diagnostics, point-of-care technologies, and public health-focused solutions.

Employment

• Dognosis India Private Limited Medical Affairs Lead
  2024 - 2025
• Mylab Discovery Solutions General Manager
  2021 - 2024
• Mylab Discovery Solutions Head
  2014 - 2021
• ICMR-National Institute of Virology Researcher
  2009 - 2014

Education

• University of Pune B Sc in Biotechnology
  2004 - 2007
• Public university of california PhD Honoris causa

Projects & Funding

Projects & funding information is unavailable.

Publications (13)

• Breath-based VOC analysis leveraging canine olfaction for multi-cancer detection: Insights from a 1000-sample study.
  Journal of Clinical Oncology 2025 DOI: 10.1200/jco.2025.43.16_suppl.1555
  +Save
• Load-and-go molecular diagnostics for human papilloma virus detection
  Journal of Allergy & Infectious Diseases 2024 DOI: 10.46439/allergy.5.046
  +Save
• Advanced integrative molecular platform for high-throughput screening of drug-resistant tuberculosis
  Diagnostic Microbiology and Infectious Disease 2024 DOI: 10.1016/j.diagmicrobio.2024.116373
  +Save
• Fast Track Diagnostic Requisite for Sepsis and its Antimicrobial Resistance in Low Resource Settings: A Step Towards Antimicrobial Stewardship
  Journal of Virology and Vaccine Development 2023 DOI: 10.53043/jvvd-3-002
  +Save
• Simultaneous detection and differentiation of dengue and chikungunya viruses for commercial utility
  VirusDisease 2023 DOI: 10.1007/s13337-023-00822-1
  +Save
• ‘CoviSwiftTM’: A point-of-care RT-PCR device for SARS-CoV-2 and its variant detection
  Journal of Virological Methods 2023 DOI: 10.1016/j.jviromet.2023.114714
  +Save
• Evaluation of a NATSpert test developed for low-resource countries for enhancing blood safety
  Global Journal of Transfusion Medicine 2020 DOI: 10.4103/gjtm.gjtm_17_20
  +Save
• NATSpert ID TripleH: A novel individual donor multiplex nucleic acid amplification test to reduce risk of transfusion-transmitted infections: Two-year experience of a blood bank in central India
  Global Journal of Transfusion Medicine 2019 DOI: 10.4103/gjtm.gjtm_54_19
  +Save
• Molecular detection and characterization of Influenza ‘C’ viruses from western India
  Infection, Genetics and Evolution 2017 DOI: 10.1016/j.meegid.2017.08.005
  +Save
• Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.
  The Indian journal of medical research 2014
  +Save